Citi Ventures is the corporate venture capital arm of Citigroup that leverages the bank’s resources to identify, incubate, and invest in innovative ideas at the intersection of finance and technology. Headquartered in San Francisco with offices in New York, London, Palo Alto, Tel Aviv, and Singapore, Citi Ventures collaborates with Citi colleagues, clients, and the broader innovation community to discover new value and accelerate the development of transformative technologies. The firm focuses on fintech, data analytics and machine learning, the future of commerce, security and enterprise IT, marketing, property technology, distributed ledger technology, and digital assets, pursuing strategic investments that complement Citi’s business lines and risk management capabilities. Since its founding, Citi Ventures has sought to build partnerships and portfolios that support entrepreneurship and technological progress, helping individuals, businesses, and communities adapt to rapid digital change while expanding Citi’s ecosystem and capabilities.
Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.